Clinical Trial Update: Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Zilucoplan (RA101495) for PNH patients inadequately responding to eculizumab; study completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Zilucoplan (zilucoplan)

Snippet

Sponsor: Ra Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: COMPLETED | Results posted: 2020-02-26